Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel I Swerdlow

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Cardiovascular Drugs and Therapy|January 27, 2016
Mendelian Randomization and Type 2 DiabetesDaniel I Swerdlow
Current Opinion in Lipidology|March 10, 2016
Genetic insights into statin-associated diabetes riskDaniel I Swerdlow, David Preiss
Diabetologia|October 23, 2014
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?Daniel I Swerdlow, Naveed Sattar
Current Cardiology Reports|April 21, 2015
Genetic risk factors and Mendelian randomization in cardiovascular diseaseDaniel I Swerdlow, Aroon D Hingorani, Steve E Humphries
British Medical Bulletin|May 12, 2012
The genetics of coronary heart diseaseDaniel I Swerdlow, Michael V Holmes, Seamus Harrison, et al.
Expert Opinion on Pharmacotherapy|September 1, 2022
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directionsLotte M de Boer, Albert Wiegman, Daniel I Swerdlow, et al.
Cardiovascular Research|March 26, 2021
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeuticsDaniel I Swerdlow, David A Rider, Arash Yavari, et al.
Atherosclerosis|April 11, 2022
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular diseaseDavid A Rider, Mona Eisermann, Kathrin Löffler, et al.
Human Genetics|March 7, 2016
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic riskVinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, et al.
JAMA Cardiology|August 4, 2016
Association of Lipid Fractions With Risks for Coronary Artery Disease and DiabetesJon White, Daniel I Swerdlow, David Preiss, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Cardiovascular Drugs and Therapy|January 27, 2016
Mendelian Randomization and Type 2 DiabetesDaniel I Swerdlow
Current Opinion in Lipidology|March 10, 2016
Genetic insights into statin-associated diabetes riskDaniel I Swerdlow, David Preiss
Diabetologia|October 23, 2014
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?Daniel I Swerdlow, Naveed Sattar
Current Cardiology Reports|April 21, 2015
Genetic risk factors and Mendelian randomization in cardiovascular diseaseDaniel I Swerdlow, Aroon D Hingorani, Steve E Humphries
British Medical Bulletin|May 12, 2012
The genetics of coronary heart diseaseDaniel I Swerdlow, Michael V Holmes, Seamus Harrison, et al.
Expert Opinion on Pharmacotherapy|September 1, 2022
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directionsLotte M de Boer, Albert Wiegman, Daniel I Swerdlow, et al.
Cardiovascular Research|March 26, 2021
Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeuticsDaniel I Swerdlow, David A Rider, Arash Yavari, et al.
Atherosclerosis|April 11, 2022
Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular diseaseDavid A Rider, Mona Eisermann, Kathrin Löffler, et al.
Human Genetics|March 7, 2016
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic riskVinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, et al.
JAMA Cardiology|August 4, 2016
Association of Lipid Fractions With Risks for Coronary Artery Disease and DiabetesJon White, Daniel I Swerdlow, David Preiss, et al.
Pageof 4